JP3946238B1 - IGF-1 level increasing agent - Google Patents
IGF-1 level increasing agent Download PDFInfo
- Publication number
- JP3946238B1 JP3946238B1 JP2006183234A JP2006183234A JP3946238B1 JP 3946238 B1 JP3946238 B1 JP 3946238B1 JP 2006183234 A JP2006183234 A JP 2006183234A JP 2006183234 A JP2006183234 A JP 2006183234A JP 3946238 B1 JP3946238 B1 JP 3946238B1
- Authority
- JP
- Japan
- Prior art keywords
- igf
- ingestion
- ovarian
- ovarian membrane
- value
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 title claims abstract description 39
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 title claims abstract description 39
- 239000012528 membrane Substances 0.000 claims abstract description 26
- 230000002611 ovarian Effects 0.000 claims abstract description 24
- 102000035195 Peptidases Human genes 0.000 claims abstract description 6
- 108091005804 Peptidases Proteins 0.000 claims abstract description 6
- 241000972773 Aulopiformes Species 0.000 claims description 3
- 235000019515 salmon Nutrition 0.000 claims description 3
- 241000251468 Actinopterygii Species 0.000 abstract description 6
- 230000032683 aging Effects 0.000 abstract description 6
- 208000024891 symptom Diseases 0.000 abstract description 5
- 230000003247 decreasing effect Effects 0.000 abstract description 3
- 241000239290 Araneae Species 0.000 abstract 1
- 230000003712 anti-aging effect Effects 0.000 abstract 1
- 230000037406 food intake Effects 0.000 description 20
- 239000003795 chemical substances by application Substances 0.000 description 14
- 239000000902 placebo Substances 0.000 description 14
- 229940068196 placebo Drugs 0.000 description 14
- 239000000706 filtrate Substances 0.000 description 8
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 6
- 150000001413 amino acids Chemical class 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 230000000052 comparative effect Effects 0.000 description 4
- 235000019688 fish Nutrition 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 239000003814 drug Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 235000010855 food raising agent Nutrition 0.000 description 3
- 241000411851 herbal medicine Species 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 210000001672 ovary Anatomy 0.000 description 3
- 239000013589 supplement Substances 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 238000004042 decolorization Methods 0.000 description 2
- 238000005238 degreasing Methods 0.000 description 2
- 238000004332 deodorization Methods 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 206010014970 Ephelides Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 206010024264 Lethargy Diseases 0.000 description 1
- 208000003351 Melanosis Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 241000382353 Pupa Species 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 230000009849 deactivation Effects 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 239000005555 hypertensive agent Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000000409 membrane extraction Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000036548 skin texture Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
Images
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
【課題】魚類の卵巣膜から抽出された成分の新たな用途を提供する。
【解決手段】魚類の卵巣膜から抽出された成分を含む抗加齢剤であり、加齢により低下したＩＧＦ−１値を再び上昇させることができ、前記加齢に伴う諸症状を緩和、改善することができる。前記卵巣膜から抽出された成分は、該卵巣膜をタンパク分解酵素で処理することにより抽出された成分である。前記卵巣膜は、鮭の卵巣膜である。
【選択図】 図２The present invention provides a new use of components extracted from ovarian membranes of fish.
An anti-aging agent comprising a component extracted from the ovarian membrane of fish, which can increase again the IGF-1 value decreased by aging, alleviating and improving various symptoms associated with the aging can do. The component extracted from the ovarian membrane is a component extracted by treating the ovarian membrane with a proteolytic enzyme. The ovarian membrane is a spider ovarian membrane.
[Selection] Figure 2
Description
本発明は、ＩＧＦ−１値上昇剤に関するものである。 The present invention relates to an agent for increasing IGF-1 level .
従来、魚類の卵巣膜（魚卵外皮）を予めオゾン水で処理した後、その構成タンパク質である筋原線維タンパク質を酵素分解してアミノ酸及びペプチドを抽出する方法が知られている（例えば特許文献１参照）。 Conventionally, a method of extracting amino acids and peptides by treating the ovarian membrane (fish egg rind) of fish with ozone water in advance and then enzymatically degrading myofibrillar protein, which is a constituent protein thereof, is known (for example, patent document). 1).
前記アミノ酸及びペプチドは、生理活性物質として、あるいは食品強化剤として用いることができるとされており、さらに詳しくは、ＡＣＥ阻害活性を備え、血圧上昇抑制剤（降圧剤）として作用するとされている。 The amino acids and peptides can be used as physiologically active substances or as food fortifiers. More specifically, the amino acids and peptides have ACE inhibitory activity and act as blood pressure increase inhibitors (hypertensive agents).
しかしながら、魚類の卵巣膜から抽出された成分には、さらに多くの用途の開発が望まれる。
本発明は、かかる事情に鑑み、魚類の卵巣膜から抽出された成分の新たな用途を提供することを目的とする。 In view of such circumstances, an object of the present invention is to provide a new use of a component extracted from the ovarian membrane of fish.
かかる目的を達成するために、本発明のＩＧＦ−１値上昇剤は、鮭の卵巣膜をタンパク分解酵素で処理することにより抽出された成分を含むことを特徴とする。 In order to achieve such an object, the agent for raising IGF-1 level of the present invention is characterized by containing a component extracted by treating the ovarian membrane of sputum with a proteolytic enzyme .
生体においては、成年期を過ぎると加齢に伴って新陳代謝が衰える、無気力になる、肌の肌理が荒くなる、つや、はりが無くなる、シミ、ソバカスが多くなる等の諸症状が現れてくる。前記加齢に伴う諸症状は、ＩＧＦ−１値の低下として把握され、通常は、一旦下降したＩＧＦ−１値が再度上昇することは無いとされている。 In the living body, after the adulthood, various symptoms appear, such as deterioration of metabolism with aging, becoming lethargic, rough skin texture, no gloss, no stickiness, more spots and freckles. The various symptoms associated with the aging are grasped as a decrease in IGF-1 value, and it is usually said that the IGF-1 value once decreased does not increase again.
ところが、本発明のＩＧＦ−１値上昇剤によれば、ＩＧＦ−１値を再び上昇させることができ、前記加齢に伴う諸症状を緩和、改善することができる。 However, according to the IGF-1 level increasing agent of the present invention, the IGF-1 level can be increased again, and various symptoms associated with the aging can be alleviated and improved.
次に、添付の図面を参照しながら本発明の実施の形態についてさらに詳しく説明する。図１は本実施形態のＩＧＦ−１値上昇剤を摂取した場合とプラセボ（偽薬）を摂取した場合とのＩＧＦ−１値の経時的変化を示すグラフ、図２は本実施形態のＩＧＦ−１値上昇剤を摂取した場合とプラセボ（偽薬）を摂取した場合とのＩＧＦ−１値の変化量を示すグラフ、図３は本実施形態のＩＧＦ−１値上昇剤を８週間摂取した後の体調と摂取中止から２週間後の体調との比較を示すグラフである。 Next, embodiments of the present invention will be described in more detail with reference to the accompanying drawings. FIG. 1 is a graph showing changes over time in IGF-1 values when an IGF-1 level-increasing agent of this embodiment is ingested and when a placebo (placebo) is ingested, and FIG. 2 is a graph showing IGF-1 of this embodiment. FIG. 3 is a graph showing the amount of change in IGF-1 value when taking a value increasing agent and when taking a placebo (placebo), FIG. 3 shows the physical condition after ingesting the IGF-1 increasing agent of this embodiment for 8 weeks It is a graph which shows the comparison with the physical condition 2 weeks after an intake stop.
本実施形態のＩＧＦ−１値上昇剤は、鮭の卵巣膜から抽出された成分（以下、卵巣膜抽出成分と略記する）を含む。前記卵巣膜抽出成分は、鮭の卵巣膜を酵素処理してタンパク質を抽出した溶液を、濾過し、得られた濾液を乾燥させる方法等により得ることができる。 The IGF-1 level increasing agent of this embodiment includes a component extracted from the ovary membrane of rabbit (hereinafter abbreviated as an ovarian membrane extraction component). The ovarian membrane extract component can be obtained by, for example, a method of filtering a solution obtained by performing enzyme treatment on the ovary membrane of salmon and drying the obtained filtrate.
前記方法では、具体的には、まず、鮭の卵巣膜を原料とし、該卵巣膜に対して水を卵巣膜：水＝１：１〜１：３の重量比で加えて撹拌、混合し、さらにタンパク分解酵素を卵巣膜の全量に対して１〜３重量％の範囲で添加し、４５〜５５℃の温度で３０分間〜５時間、好ましくは２時間加熱する。このようにすると、前記卵巣膜の成分のうち、前記タンパク分解酵素で分解された成分が水中に溶出し、該成分の水溶液が得られる。 Specifically, in the method, first, the ovarian membrane of the pupa is used as a raw material, and water is added to the ovarian membrane in a weight ratio of ovarian membrane: water = 1: 1 to 1: 3, and the mixture is stirred and mixed. Furthermore, a proteolytic enzyme is added in the range of 1 to 3% by weight with respect to the total amount of the ovarian membrane, and heated at a temperature of 45 to 55 ° C. for 30 minutes to 5 hours, preferably 2 hours. If it does in this way, the component decomposed | disassembled with the said proteolytic enzyme will elute in water among the components of the said ovary membrane, and the aqueous solution of this component will be obtained.
次に、前記水溶液に含まれている前記タンパク分解酵素を失活する。前記失活は、例えば、前記水溶液を９０℃の温度で５分間加熱することにより行うことができる。 Next, the proteolytic enzyme contained in the aqueous solution is inactivated. The deactivation can be performed, for example, by heating the aqueous solution at a temperature of 90 ° C. for 5 minutes.
次に、前記水溶液を３０メッシュ程度の金網で簡易濾過し、未分解の卵巣膜等の粗大物を除去する。そして、得られた濾液に活性炭を添加して、該濾液の脱臭、脱色、脱脂を行う。前記濾液の脱臭、脱色、脱脂は、前記原料としての卵巣膜の全量に対して２〜４重量％の範囲の活性炭を該濾液に添加し、例えば６０℃の温度で３０分間加熱することにより行うことができる。 Next, the aqueous solution is simply filtered through a wire mesh of about 30 mesh to remove coarse materials such as undecomposed ovarian membranes. Then, activated carbon is added to the obtained filtrate to deodorize, decolorize, and degrease the filtrate. The deodorization, decolorization, and degreasing of the filtrate is performed by adding activated carbon in the range of 2 to 4% by weight to the total amount of the ovarian membrane as the raw material and heating the filtrate at a temperature of 60 ° C. for 30 minutes, for example. be able to.
前記活性炭による脱臭、脱色、脱脂処理後、前記濾液を例えばフィルタープレスにより濾過し、得られた濾液を、減圧下、例えば６０℃の温度で濃縮した後、例えば８０℃の温度に１０分間維持して滅菌する。そして、滅菌後の前記濾液をスプレードライにて乾燥させることにより、前記卵巣膜抽出成分を得ることができる。前記卵巣膜抽出成分は、アミノ酸、ペプチド、ビタミン、ミネラル、糖類、酵素、核酸及びその代謝物、各種成長因子、サイトカイン等を含んでいる。 After the deodorization, decolorization, and degreasing treatment with the activated carbon, the filtrate is filtered by, for example, a filter press, and the obtained filtrate is concentrated at a temperature of 60 ° C. under reduced pressure, for example, and then maintained at a temperature of 80 ° C. for 10 minutes, for example. And sterilize. Then, the ovarian membrane extract component can be obtained by drying the sterilized filtrate by spray drying. The ovarian membrane extract component contains amino acids, peptides, vitamins, minerals, sugars, enzymes, nucleic acids and their metabolites, various growth factors, cytokines, and the like.
本実施形態のＩＧＦ−１値上昇剤は、前記卵巣膜抽出成分を、例えば錠剤等の形に製剤したものであり、例えば健康食品等の食品として摂取することにより、加齢により低下したＩＧＦ−１値を再び上昇させることができ、前記加齢に伴う諸症状を緩和、改善することができる。 The IGF-1 level increasing agent of the present embodiment is prepared by, for example, formulating the ovarian membrane extract component in the form of a tablet or the like. 1 value can be raised again, and various symptoms accompanying the aging can be alleviated and improved.
次に、本発明の実施例と比較例とを示す。 Next, examples of the present invention and comparative examples will be described.
本実施例では、まず、鮭の卵巣膜抽出成分を錠剤の形に製剤して、ＩＧＦ−１値上昇剤を製造した。前記錠剤は、前記卵巣膜抽出物２４５ｍｇ、賦形剤（ラブリワックス（登録商標））５ｍｇからなり、８ｍｍの直径を備えている。 In this example, first, an ovarian membrane extract component of salmon was formulated in the form of a tablet to produce an IGF-1 increasing agent . The tablet consists of 245 mg of the ovarian membrane extract and 5 mg of excipient (Loveli wax (registered trademark)) and has a diameter of 8 mm.
次に、３８〜４２歳の健康な女性モニター１０名に、前記錠剤を健康食品として１日当たり４錠、８週間に亘って摂取させた。尚、各モニターは、１ヶ月前からサプリメント、薬品（漢方薬を含む）の摂取を行っていない。 Next, 10 healthy female monitors aged 38 to 42 years old took 4 tablets per day for 8 weeks as a health food. Each monitor has not taken supplements or medicines (including herbal medicines) since one month ago.
そして、摂取開始前、摂取開始４週間目、摂取開始８週間目に、血液検査を行い、ＩＧＦ−１値を測定した。前記モニター１０人のＩＧＦ−１値の平均値を図１に、摂取開始から４週間目まで、摂取開始から８週間目までのＩＧＦ−１値の平均値の変化量を図２に、それぞれ示す。尚、図１中、摂取開始前を「０週」、摂取開始４週間目を「４週」、摂取開始８週間目を「８週」と記載し、図２中、摂取開始から４週間目までを「０−４週」、摂取開始から８週間目までを「０−８週」と記載する。 And before the start of ingestion, 4 weeks after the start of ingestion and 8 weeks after the start of ingestion, a blood test was performed to measure the IGF-1 value. The average value of IGF-1 values of the 10 monitors is shown in FIG. 1, and the amount of change in the average value of IGF-1 values from the start of intake to the 4th week and from the start of intake to the 8th week is shown in FIG. . In FIG. 1, “0 week” is shown before the start of ingestion, “4 weeks” is the 4th week of ingestion, and “8 weeks” is the 8th week of ingestion. “0-4 weeks” and “8-8 weeks” from the start of intake are described.
また、各モニターの自己申告による体調について、摂取開始８週間目と、摂取中止から２週間後との状態を比較した。結果を図３に示す。
〔比較例〕
本比較例では、まず、前記実施例のＩＧＦ−１値上昇剤に代えて、コーンスターチ１２５ｍｇ、乳糖１２５ｍｇからなるプラセボ（偽薬）を、直径８ｍｍの錠剤の形に製剤した。
次に、前記実施例とは異なる３８〜４２歳の健康な女性モニター１０名に、前記偽薬のカプセル剤を１日当たり４錠、８週間に亘って投与した。尚、各モニターは、１ヶ月前からサプリメント、薬品（漢方薬を含む）の摂取を行っていない。
Moreover, regarding the physical condition by self-report of each monitor, the state of the 8th week from the start of intake and the state after 2 weeks from the stop of intake were compared. The results are shown in FIG.
[Comparative Example]
In this comparative example, first, a placebo (placebo) consisting of 125 mg of corn starch and 125 mg of lactose was formulated in the form of a tablet with a diameter of 8 mm instead of the IGF-1 level increasing agent of the above example.
Next, the placebo capsules were administered 4 times a day for 8 weeks to 10 healthy female monitors aged 38 to 42 years different from the Examples. Each monitor has not taken supplements or medicines (including herbal medicines) since one month ago.
次に、前記実施例とは異なる３８〜４２歳の健康な女性モニター１０名に、前記偽薬のカプセル剤を１日当たり４錠、８週間に亘って投与した。尚、各モニターは、１ヶ月前からサプリメント、薬品（漢方薬を含む）の摂取を行っていない。 Next, the placebo capsules were administered 4 times a day for 8 weeks to 10 healthy female monitors aged 38 to 42 years different from the Examples. Each monitor has not taken supplements or medicines (including herbal medicines) since one month ago.
そして、前記実施例と全く同一にして、ＩＧＦ−１値を測定した。前記モニター１０人のＩＧＦ−１値の平均値を図１に、摂取開始４週間目、摂取開始８週間目のＩＧＦ−１値の平均値の変化量を図２に、それぞれ示す。 Then, the IGF-1 value was measured in exactly the same manner as in the above example. The average value of the IGF-1 values of the 10 monitors is shown in FIG. 1, and the amount of change in the average value of the IGF-1 values at the 4th week of ingestion and the 8th week of ingestion is shown in FIG.
図１から、本実施形態のＩＧＦ−１値上昇剤（実施例）によれば、摂取開始４週間目には摂取開始前に比較してＩＧＦ−１値が増加しており、摂取開始８週間目には摂取開始４週間目よりもさらに増加しており、単調に増加していることが明らかである。これに対して、プラセボ（比較例）によれば、摂取開始８週間目には摂取開始前に比較してＩＧＦ−１値が増加しているものの、摂取開始４週間目には摂取開始前に比較して一旦ＩＧＦ−１値が減少しており、単調な増加ではないことが明らかである。 From FIG. 1, according to the IGF-1 level-increasing agent (Example) of the present embodiment, the IGF-1 value increased in the 4th week after ingestion compared to before the start of ingestion, and 8 weeks after the start of ingestion. In the eyes, it is further increased than the fourth week after ingestion, and it is apparent that the number is increasing monotonously. On the other hand, according to the placebo (comparative example), the IGF-1 value increased in the 8th week after ingestion compared to before the start of ingestion, but before the start of ingestion in the 4th week after ingestion. In comparison, it is clear that the IGF-1 value has once decreased and is not a monotonous increase.
また、図２から、本実施形態のＩＧＦ−１値上昇剤によれば、ＩＧＦ−１値の増加量がプラセボよりも大きいことが明らかである。 Moreover, it is clear from FIG. 2 that the amount of increase in the IGF-1 value is greater than that of the placebo according to the IGF-1 value increasing agent of the present embodiment.
さらに、図３から、本実施形態のＩＧＦ−１値上昇剤を摂取開始後、８週間目の体調の方が、摂取中止から２週間後の体調よりも優れていることが明らかである。これは、本実施形態のＩＧＦ−１値上昇剤を摂取開始後、８週間目には、ＩＧＦ−１値の増加により体調が好転していたものが、摂取中止に伴いＩＧＦ−１値増加の効果が低減したものと考えられる。 Furthermore, it is clear from FIG. 3 that the physical condition at 8 weeks after the start of ingestion of the IGF-1 level-increasing agent of this embodiment is superior to the physical condition at 2 weeks after ingestion. This is because in 8 weeks after the start of ingestion of the IGF-1 level increasing agent of this embodiment, the physical condition improved due to the increase in IGF-1 value, but the increase in IGF-1 value with the discontinuation of intake It is thought that the effect was reduced.
符号なし。 No sign.
Claims (1)
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2006183234A JP3946238B1 (en) | 2006-07-03 | 2006-07-03 | IGF-1 level increasing agent |
| KR1020070066257A KR101301037B1 (en) | 2006-07-03 | 2007-07-02 | Antiaging agent |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2006183234A JP3946238B1 (en) | 2006-07-03 | 2006-07-03 | IGF-1 level increasing agent |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP3946238B1 true JP3946238B1 (en) | 2007-07-18 |
| JP2008013441A JP2008013441A (en) | 2008-01-24 |
Family
ID=38344678
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006183234A Active JP3946238B1 (en) | 2006-07-03 | 2006-07-03 | IGF-1 level increasing agent |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP3946238B1 (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1938866A2 (en) * | 2006-12-22 | 2008-07-02 | Nippon Barrier Free Co. Ltd. | Cosmetic product comprising a component extracted from a Salmonidae fish ovarian |
| JP4643754B1 (en) * | 2010-07-02 | 2011-03-02 | 株式会社日本バリアフリー | Hair restorer |
| JP2012255036A (en) * | 2012-10-02 | 2012-12-27 | Nippon Barrier Free:Kk | Anti-aging agent |
| WO2014103410A1 (en) | 2012-12-26 | 2014-07-03 | 森永乳業株式会社 | Igf-1 production promoter |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5449730B2 (en) | 2008-09-29 | 2014-03-19 | 協和薬品株式会社 | Menopause ameliorant and nutritional supplement |
-
2006
- 2006-07-03 JP JP2006183234A patent/JP3946238B1/en active Active
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1938866A2 (en) * | 2006-12-22 | 2008-07-02 | Nippon Barrier Free Co. Ltd. | Cosmetic product comprising a component extracted from a Salmonidae fish ovarian |
| EP1938866A3 (en) * | 2006-12-22 | 2009-04-08 | Nippon Barrier Free Co. Ltd. | Cosmetic product comprising a component extracted from a Salmonidae fish ovarian |
| JP4643754B1 (en) * | 2010-07-02 | 2011-03-02 | 株式会社日本バリアフリー | Hair restorer |
| JP2012012354A (en) * | 2010-07-02 | 2012-01-19 | Nippon Barrier Free:Kk | Hair growth promoter |
| JP2012255036A (en) * | 2012-10-02 | 2012-12-27 | Nippon Barrier Free:Kk | Anti-aging agent |
| WO2014103410A1 (en) | 2012-12-26 | 2014-07-03 | 森永乳業株式会社 | Igf-1 production promoter |
| US9801404B2 (en) | 2012-12-26 | 2017-10-31 | Morinaga Milk Industry Co., Ltd. | IGF-1 production-promoting agent |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2008013441A (en) | 2008-01-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4669920B2 (en) | Functional material that suppresses blood glucose rise and blood pressure rise | |
| JP5916387B2 (en) | Dipeptidyl peptidase-4 inhibitor | |
| JP3946238B1 (en) | IGF-1 level increasing agent | |
| JPH09176019A (en) | Carbohydrate-degradative/digestive enzyme inhibitor and medicine and food/beverage formulated therewith | |
| JP5027001B2 (en) | Enzyme-treated royal jelly and skin fibroblast growth promoter containing the same | |
| JP4917584B2 (en) | Processed solubilized bees, method for producing the same, antioxidant, ACE inhibitor, antihypertensive agent, dermal fibroblast proliferation promoter, fatigue recovery agent, blood flow improving agent, and solubilized bees Pharmaceuticals, cosmetics or food / drinks contained | |
| CN109090597A (en) | A kind of auxiliary lower hyperlipidemia, hypertension, hyperglycemia composition and its preparation method and application | |
| JP3899116B1 (en) | Skin roughening agent | |
| KR102302933B1 (en) | Preparation of fermented garlic mixture and manufacturing method of composition effective for cardiovascular disease | |
| JP2012025718A (en) | Oral preparation for improving pores | |
| JP7229513B2 (en) | Brain function improving agent and food and drink for improving brain function | |
| JP2008007417A (en) | Oral administration composition for amelioration/prevention of eyestrain caused by ciliary hypermyotonia | |
| CN106434806A (en) | Cordyceps militaris polypeptide as well as preparation method and applications thereof | |
| JP2008007417A5 (en) | ||
| JP3946239B1 (en) | Accelerating pulse wave aging index raising agent | |
| AU2012354703B2 (en) | Hydroxymethylfurfural derivative | |
| KR20130006170A (en) | Composition for blood sugar regulation comprising soybean hydrololysate with high chp(cyclo(his-pro)) | |
| JP2008037770A (en) | Anti-aging agent | |
| JP2005179235A (en) | Composition for preventing, treating or ameliorating disorder of feeling comprising specific molecular weight fraction obtained from water-soluble fraction of royal jelly or treated royal jelly as active ingredient | |
| JP2670742B2 (en) | α-amylase inhibitor | |
| JP2011036241A (en) | Method for preparation of angiotensin-converting enzyme inhibitor peptide | |
| KR102208654B1 (en) | Composition comprising banana peel extract for regulating expressions of tph1 gene, ddc gene and/or aanat gene | |
| JP2016150910A (en) | Endurance-improving agent | |
| JP2017195830A (en) | Food composition for adiposity prevention | |
| JP2007063236A (en) | Composition for improving quality of sleep |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20070320 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20070410 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 3946238 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100420 Year of fee payment: 3 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110420 Year of fee payment: 4 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120420 Year of fee payment: 5 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130420 Year of fee payment: 6 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20140420 Year of fee payment: 7 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |